Please login to the form below

Not currently logged in

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”


Bristol-Myers Squibb has issued a defence of its proposed $74bn merger, with Celgene as an activist fund steps up its attempts to rouse resistance to the deal.

Rebel investment group Starboard Value, which was the first to break ranks and voice its opposition to the acquisition late last month, said yesterday it had sent a letter to BMS stockholders reiterating its concerns and had filed ‘blue proxy’ materials to urge them to vote against it at or before a 12 April shareholder meeting.

BMS isn’t standing idle, and published a 46-page presentation detailing the “clear strategic rationale” and “compelling value proposition” for the merger on a new website, as well as filing its own ‘white proxy’ card to allow investors to back it.

Starboard has around a 1% share in BMS but saw its position strengthened a few days ago when larger investor Wellington Management – which owns around 7.7% of the company’s stock – joined the cause. Wellington said the deal undervalues BMS, is risky to execute, and ignores alternative options to create value for shareholders.

The activist investors claim that BMS is buying a company with a massive patent cliff – principally blood cancer blockbuster Revlimid (lenalidomide) – which they say will requite Celgene to replace 60% of its revenue in the next seven years.

They also claim Celgene’s R&D pipeline is “extremely risky”, overvalued and will require significant funding to bring to fruition, and that the entire transaction has been cobbled together hastily, possibly to avert the threat of a takeover of BMS itself. They see more value in BMS continuing as an independent company or in a potential sale, although there seems little sense among analysts that the latter eventuality is realistic.

BMS has its own list of reasons why the Celgene combination makes sense, topped by the claim the merger will create a company that is number one in oncology and cardiovascular and in the top five in immunology and inflammation – with nine products with more than $1bn in annual sales.

The Celgene pipeline “includes five differentiated late-stage assets with low clinical risk, expected near-term approvals and incremental value creation,” along with more than 20 earlier-stage candidates and an immediate presence in cell therapy for cancer, it asserts.

The acquisition of Celgene provides advantages with less risk compared to other strategic alternatives, including a strategy of pursuing several smaller transactions or staying independent, continues BMS.

“We believe the choice for shareholders is clear. Vote the WHITE proxy card “FOR” a better company, with greater potential to create value,” says the company in its own letter to shareholders.

Article by
Phil Taylor

7th March 2019

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...